Objective　To　evaluate　the　safety　and　effectiveness　of　a　vaccine　based　on　latent　membrane　protein　2　(LMP2)　modified　dendritic　cells　(DCs)　that　boosts　specific　responses　of　cytotoxic　T　lymphocytes　(CTLs)　to　LMP2　before　and　after　intradermal　injection　in　patients　with　nasopharyngeal　carcinoma　(NPC).　Methods　DCs　were　derived　from　peripheral　blood　monocytes　of　patients　with　NPC.　We　prepared　LMP2-DCs　infected　by　recombinant　adenovirus　vector　expressing　LMP2　(rAd-LMP2).　NPC　patients　were　immunized　with　2　x　10(5)　LMP2-DCs　by　intradermal　injection　at　week　0　and　after　the　second　and　fourth　weeks.　Specific　responses　to　LMP2　were　detected　by　enzyme-linked　immunospot　(ELISPOT)　assay　at　week　0　and　at　the　fifth　and　eighth　weeks.　Local　clinicians　performed　the　follow-up　and　tracking　of　patients.　Results　We　demonstrated　that　DCs　derived　from　monocytes　displayed　typical　DC　morphologies;　the　expression　of　LMP2　in　the　LMP2-DCs　vaccine　was　confirmed　by　immunocytochemical　assay.　Twenty-nine　patients　with　NPC　were　enrolled　in　this　clinical　trial.　The　LMP2-DCs　vaccine　was　well　tolerated　in　all　of　the　patients.　Boosted　responses　to　LMP2　peptide　sub-pools　were　observed　in　18　of　the　29　patients　with　NPC.　The　follow-up　data　of　29　immunized　patients　from　April,　2010　to　April　2015　indicated　a　five-year　survival　rate　of　94.4%　in　responders　and　45.5%　in　non-responders.　Conclusion　In　this　pilot　study,　we　demonstrated　that　the　LMP2-DCs　vaccine　is　safe　and　effective　in　patients　with　NPC.　Specific　CTLs　responses　to　LMP2　play　a　certain　role　in　controlling　and　preventing　the　recurrence　and　metastasis　of　NPC,　which　warrants　further　clinical　testing.